MEN1703 (SEL24)

SEL24 · Ryvu Therapeutics SA

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MEN1703 (SEL24), covering 2025-04-29 to 2025-09-29. Get the full timeline:

Most recent: Clinical Trial Update: MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) [Phase 2]